|Bid||89.61 x 1400|
|Ask||92.55 x 1400|
|Day's Range||90.01 - 90.96|
|52 Week Range||76.62 - 100.15|
|Beta (3Y Monthly)||0.58|
|PE Ratio (TTM)||25.59|
|Earnings Date||May 23, 2019|
|Forward Dividend & Yield||2.00 (2.21%)|
|1y Target Est||103.38|
March 25, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced the launch of the Medtronic MedTech Innovation Accelerator in Pujiang International Science and Technology City at Minhang District, Shanghai. The new collaborative innovation platform will provide services for MedTech start-ups worldwide, address unmet clinical needs in China, and welcome its initial roster of portfolio companies.
Homeland Security has issued a warning for a set of critical-ratedvulnerabilities in Medtronic defibrillators that put the devices at risk ofmanipulation
Last year, Medtronic disabled internet updates for some 34,000 CareLink programming devices that healthcare providers around the world use to access implanted pacemakers, saying the system was vulnerable to cyberattacks. Medical device makers have bolstered efforts to mitigate product security vulnerabilities in recent years following a flurry of warnings from security researchers who have identified bugs in devices like the Medtronic implant programmers.
A Food and Drug Administration probe into chemotherapy drug paclitaxel is testing the waters for medical device companies SurModics, Boston Scientific, Medtronic and Becton Dickinson.
The use of Abbott's (ABT) HeartMate 3 pump can efficiently prolong life -term and improve the quality of life for advanced heart failure patients.
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.
Edwards stock jumped to a record high Monday after the medtech company's TAVR heart-valve replacement outperformed surgery in a yearlong clinical study. Medtronic and Boston stocks sank.
Late-Breaking Trial Results Presented at ACC Scientific Sessions and Published in The New England Journal of Medicine WRAP-IT is the Largest Randomized Global Trial Ever Conducted with Cardiac Implanted ...
March 16, 2019 - Medtronic plc (MDT) today announced first-ever clinical data from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut(TM) transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients.
Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday. Both companies already have approvals for their TAVR (transcatheter aortic valve replacement) systems for use in patients too frail to endure surgery and those deemed at intermediate risk. An estimated 165,000 low-risk patients suffer from severe aortic stenosis each year in the United States, Western Europe and Japan, a condition that can lead to heart failure in as little as two years, Medtronic said.
It was only a 0.09% stumble for the S&P 500, but suspiciously, Thursday's high was once again the same ceiling the market has been dancing with since mid-October.Facebook (NASDAQ:FB) proved to be the biggest drag, slipping 1.9% in regular-hours trading only to slip another 1.9% in after-hours action following a myriad of less-than-great news. Not only is product chief Chris Cox stepping down, investors remain concerned about the social networking site's major outage and now the company is dealing with a criminal investigation about the way it handled and shared some data. Dollar General (NYSE:DG) suffered a much bigger loss though, losing 7.5% after a disappointing fourth-quarter report.There were some winners, like Snap (NYSE:SNAP), which gained 12.2% following an upgrade from long-term bear BTIG analyst Richard Greenfield. There just weren't enough names like Snap to get the broad market over the hump.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAs Friday's trading gets started, it's the stock charts of Lamb Weston Holdings (NYSE:LW), LKQ (NASDAQ:LKQ) and Medtronic (NYSE:MDT) that are worthy of a closer technical look. Here's why, and what to look for. Medtronic (MDT)Back in early January, Medtronic was pegged as a rebound candidate. Though the downtrend was strong, it was so strong it flushed out the last of the would-be sellers. A well-established support line was touched, bolstering the case for a bounce. * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% That happened exactly as expected. MDT shares roared back, crossing all the key moving average lines in the process. In fact, thanks to last week's and this week's action, the odds of even more upside were just raised. Click to Enlarge • The key to the next leg up lies in the March 8 pivot, marked by a long-tailed low and indicated with a blue "up" arrow. That move washed out any doubters before the buyers went back to work.• Zooming out to the weekly chart, we can see the underpinning of the bigger-picture rebound. The January low was made by an encounter with the same floor that sparked the past two major rebounds.• The next most likely technical ceiling is around $94, plotted with a blue dashed line on the daily chart. Above that level, there's little left to hold a rally back. Lamb Weston Holdings (LW)The bulls have been putting up a valiant fight trying to keep Lamb Weston Holdings shares from imploding. But after weeks of failure to get traction, the effort is collapsing. Yesterday's 2.3% tumble has brought the stock within striking distance of a major technical floor, and the number of sellers continues to grow. Click to Enlarge • The make-or-break line is $67.85, plotted with a yellow dashed line on both stock charts.• Shares of Lamb Weston were already finding resistance at both moving average lines, but the purple 50-day moving average line recently crossed below the white 200-day line, creating a so-called 'death cross' that portends more selling.• It has been subtle so far, but as is evident on the daily chart, we're seeing increasingly above-average selling volume from time to time now. LKQ (LKQ)Finally, at the very beginning of this month LKQ was highlighted as a bullish candidate. Although it had been trending higher at the time, a steep pullback immediately followed a sharp recovery move sent a clear message that the bulls were serious.And they were. The stock edged a little higher the next few days. Though they peeled back in the meantime, over the course of the past couple of days the buyers have tipped their hand again. And, they've dropped ideal clues in the process. Click to Enlarge • The key clue is the volume. The buying volume before and after the recent lull was on below-average volume, while the rally effort before and after was a high volume affair.• Also note that we've made the first higher lows since 2018, as marked with a rising, blue dashed line on both stock charts.• The clincher will be a cross above the 200-day moving average line, plotted in white, currently at $29.56.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Stocks Sitting on Huge Piles of Cash * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 7 Dividend Stocks With Big Yields Compare Brokers The post 3 Big Stock Charts for Friday: Medtronic, LKQ and Lamb Weston appeared first on InvestorPlace.
March 14, 2019 - Medtronic plc (MDT) today announced that its Board of Directors has appointed Andrea J. Goldsmith, Ph.D. to the Board as an independent director, effective March 11, 2019. Dr. Goldsmith is the Stephen Harris professor in the School of Engineering at Stanford University and director of Stanford`s Wireless Systems Laboratory.
Medtronic PLC NYSE:MDTView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for MDT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MDT. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold MDT had net inflows of $5.19 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Med-tech giant Medtronic said Friday its board of directors had approved another $6 billion in stock buybacks, continuing surge in interest by corporations in purchasing their own shares.
On 25 January 2019, Medtronic plc (NYSE:MDT) released its earnings update. Generally, analysts seem cautiously optimistic, as a 19% increase in profits is expected in the upcoming year, relative toRead More...
Medtronic PLC said late Friday its board authorized a new plan to buy back up to $6 billion in shares. Prior to the new plan, the medical device company said it has $1.3 billion in share buyback authorization left in a $5 billion plan approved in June 2017. Shares of Medtronic ticked 1% higher in the extended session Friday, and are up 10% over the past 12 months, compared with a 0.2% gain in the S&P 500 index .
March 8, 2018 - The board of directors of Medtronic plc (MDT) today approved the fiscal year 2019 fourth quarter cash dividend of $0.50 per ordinary share, representing a 9 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2018. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 41 consecutive years. In addition to approving the dividend, the board today authorized the expenditure of funds for share repurchases.